000299843 001__ 299843
000299843 005__ 20250319112305.0
000299843 0247_ $$2doi$$a10.62347/STQK5435
000299843 0247_ $$2pmid$$apmid:40092088
000299843 0247_ $$2pmc$$apmc:PMC11909532
000299843 037__ $$aDKFZ-2025-00580
000299843 041__ $$aEnglish
000299843 082__ $$a610
000299843 1001_ $$aLi, Dapeng$$b0
000299843 245__ $$aCCCTC-binding factor regulates splicing factor proline and glutamine-rich to promote malignant growth of osteosarcoma.
000299843 260__ $$aMadison, Wis.$$be-Century Publishing Corporation$$c2025
000299843 3367_ $$2DRIVER$$aarticle
000299843 3367_ $$2DataCite$$aOutput Types/Journal article
000299843 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1742294246_12554
000299843 3367_ $$2BibTeX$$aARTICLE
000299843 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000299843 3367_ $$00$$2EndNote$$aJournal Article
000299843 500__ $$aProteomics and Cancer Cell Signaling Group, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany
000299843 520__ $$aCCCTC-binding factor (CTCF) is a candidate tumor regulatory gene that encodes multifunctional transcription factors. While its role in various cancers has been studied, its function and mechanism in osteosarcoma were uncertain. Previous studies have identified splicing factor proline and glutamine-rich (SFPQ) as an oncogene in osteosarcoma. Bioinformatic analysis suggested that CTCF may regulate SFPQ transcriptionally. This study aimed to elucidate the role of CTCF in osteosarcoma and explore its possible regulatory relationship with SFPQ.Potential transcription factors of SFPQ were identified using an online transcription factor analysis database. The expression levels of CTCF in osteosarcoma cells were assessed using quantitative real-time PCR (qRT-PCR) and western blotting (WB). The effect of CTCF and SFPQ on osteosarcoma cell behavior was evaluated through cell function assays, dual-luciferase reporter assays, and rescue experiments.Database analyses (hTFtarget and GEPIA2) indicated a moderate correlation between CTCF and SFPQ. qRT-PCR and WB results confirmed significant CTCF expression in osteosarcoma cells. Overexpression of CTCF enhanced cell proliferation, migration, and invasion. Furthermore, CTCF was found to bind to the promoter region of SFPQ, leading to its upregulation. Rescue experiments demonstrated that SFPQ knockdown attenuated the oncogenic effects of CTCF overexpression.CTCF functions as an oncogene in osteosarcoma by positively regulating SFPQ expression, thereby promoting the malignant properties of osteosarcoma cells. These findings suggest that targeting the CTCF-SFPQ axis may be a therapeutic strategy for osteosarcoma.
000299843 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000299843 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000299843 650_7 $$2Other$$aCTCF
000299843 650_7 $$2Other$$aOsteosarcoma
000299843 650_7 $$2Other$$aSFPQ
000299843 650_7 $$2Other$$abiological behavior
000299843 650_7 $$2Other$$atranscription factor
000299843 7001_ $$aYang, Yang$$b1
000299843 7001_ $$aYin, Zhengyu$$b2
000299843 7001_ $$0P:(DE-He78)507c97fafa917642c6757c53a3ca3383$$aMao, Lianghao$$b3$$udkfz
000299843 7001_ $$aZhang, Yiming$$b4
000299843 7001_ $$aJiang, Pan$$b5
000299843 7001_ $$aZhu, Tianxiang$$b6
000299843 7001_ $$aHe, Tongchuan$$b7
000299843 7001_ $$aZhong, Xinyu$$b8
000299843 7001_ $$aZheng, Qiping$$b9
000299843 7001_ $$aZhang, Wenchao$$b10
000299843 773__ $$0PERI:(DE-600)2471058-1$$a10.62347/STQK5435$$gVol. 17, no. 2, p. 1495 - 1509$$n2$$p1495 - 1509$$tAmerican journal of translational research$$v17$$x1943-8141$$y2025
000299843 909CO $$ooai:inrepo02.dkfz.de:299843$$pVDB
000299843 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)507c97fafa917642c6757c53a3ca3383$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000299843 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000299843 9141_ $$y2025
000299843 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000299843 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000299843 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
000299843 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000299843 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-20
000299843 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000299843 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000299843 9201_ $$0I:(DE-He78)A400-20160331$$kA400$$lKKE Pädiatrische Leukämie$$x0
000299843 980__ $$ajournal
000299843 980__ $$aVDB
000299843 980__ $$aI:(DE-He78)A400-20160331
000299843 980__ $$aUNRESTRICTED